Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, et al. Global burden of cardiovascular diseases and risk factors, 1990–2019: update from the GBD 2019 study. J Am Coll Cardiol. 2020;76(25):2982–3021.

Article  PubMed  PubMed Central  Google Scholar 

Gordon T, Kannel WB. Premature mortality from coronary heart disease. The Framingham study. JAMA. 1971;215(10):1617–25.

Article  CAS  PubMed  Google Scholar 

Stamler J, Wentworth D, Neaton JD. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA. 1986;256(20):2823–8.

Article  CAS  PubMed  Google Scholar 

Verschuren WM, Jacobs DR, Bloemberg BP, Kromhout D, Menotti A, Aravanis C, et al. Serum total cholesterol and long-term coronary heart disease mortality in different cultures. Twenty-five-year follow-up of the seven countries study. JAMA. 1995;274(2):131–6.

Article  CAS  PubMed  Google Scholar 

Apostolopoulou M, Corsini A, Roden M. The role of mitochondria in statin-induced myopathy. Eur J Clin Invest. 2015;45(7):745–54.

Article  CAS  PubMed  Google Scholar 

Thompson PD, Panza G, Zaleski A, Taylor B. Statin-associated side effects. J Am Coll Cardiol. 2016;67(20):2395–410.

Article  CAS  PubMed  Google Scholar 

Auer J, Sinzinger H, Franklin B, Berent R. Muscle- and skeletal-related side-effects of statins: tip of the iceberg? Eur J Prev Cardiol. 2016;23(1):88–110.

Article  PubMed  Google Scholar 

Sirtori CR. The pharmacology of statins. Pharmacol Res. 2014;88:3–11.

Article  CAS  PubMed  Google Scholar 

Baker SK, Tarnopolsky MA. Statin myopathies: pathophysiologic and clinical perspectives. Clin Invest Med. 2001;24(5):258–72.

CAS  PubMed  Google Scholar 

Hamelin BA, Turgeon J. Hydrophilicity/lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors. Trends Pharmacol Sci. 1998;19(1):26–37.

Article  CAS  PubMed  Google Scholar 

Nezasa K, Higaki K, Takeuchi M, Nakano M, Koike M. Uptake of rosuvastatin by isolated rat hepatocytes: comparison with pravastatin. Xenobiotica. 2003;33(4):379–88.

Article  CAS  PubMed  Google Scholar 

Filppula AM, Hirvensalo P, Parviainen H, Ivaska VE, Lonnberg KI, Deng F, et al. Comparative hepatic and intestinal metabolism and pharmacodynamics of statins. Drug Metab Dispos. 2021;49(8):658–67.

Article  CAS  PubMed  Google Scholar 

Climent E, Benaiges D, Pedro-Botet J. Hydrophilic or lipophilic statins? Front Cardiovasc Med. 2021;8: 687585.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Choudhary A, Rawat U, Kumar P, Mittal P. Pleotropic effects of statins: the dilemma of wider utilization of statin. Egypt Heart J. 2023;75(1):1.

Article  PubMed  PubMed Central  Google Scholar 

Liu A, Wu Q, Guo J, Ares I, Rodriguez JL, Martinez-Larranaga MR, et al. Statins: adverse reactions, oxidative stress and metabolic interactions. Pharmacol Ther. 2019;195:54–84.

Article  CAS  PubMed  Google Scholar 

Jeong HJ, Lee HS, Kim KS, Kim YK, Yoon D, Park SW. Sterol-dependent regulation of proprotein convertase subtilisin/kexin type 9 expression by sterol-regulatory element binding protein-2. J Lipid Res. 2008;49(2):399–409.

Article  CAS  PubMed  Google Scholar 

Huijgen R, Fouchier SW, Denoun M, Hutten BA, Vissers MN, Lambert G, et al. Plasma levels of PCSK9 and phenotypic variability in familial hypercholesterolemia. J Lipid Res. 2012;53(5):979–83.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bilheimer DW, Grundy SM, Brown MS, Goldstein JL. Mevinolin and colestipol stimulate receptor-mediated clearance of low density lipoprotein from plasma in familial hypercholesterolemia heterozygotes. Proc Natl Acad Sci USA. 1983;80(13):4124–8.

Article  ADS  CAS  PubMed  PubMed Central  Google Scholar 

Forstermann U, Li H. Therapeutic effect of enhancing endothelial nitric oxide synthase (eNOS) expression and preventing eNOS uncoupling. Br J Pharmacol. 2011;164(2):213–23.

Article  PubMed  PubMed Central  Google Scholar 

Banach M, Stulc T, Dent R, Toth PP. Statin non-adherence and residual cardiovascular risk: There is need for substantial improvement. Int J Cardiol. 2016;225:184–96.

Article  PubMed  Google Scholar 

Stroes ES, van der Valk FM. A sense of excitement for a specific Lp(a)-lowering therapy. Lancet. 2015;386(10002):1427–9.

Article  PubMed  Google Scholar 

Newman CB, Preiss D, Tobert JA, Jacobson TA, Page RL 2nd, Goldstein LB, et al. Statin safety and associated adverse events: a scientific statement from the American Heart Association. Arterioscler Thromb Vasc Biol. 2019;39(2):e38–81.

Article  CAS  PubMed  Google Scholar 

Bruckert E, Hayem G, Dejager S, Yau C, Begaud B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients–the PRIMO study. Cardiovasc Drugs Ther. 2005;19(6):403–14.

Article  CAS  PubMed  Google Scholar 

Nichols GA, Koro CE. Does statin therapy initiation increase the risk for myopathy? An observational study of 32,225 diabetic and nondiabetic patients. Clin Ther. 2007;29(8):1761–70.

Article  CAS  PubMed  Google Scholar 

Cohen JD, Brinton EA, Ito MK, Jacobson TA. Understanding Statin Use in America and Gaps in Patient Education (USAGE): an internet-based survey of 10,138 current and former statin users. J Clin Lipidol. 2012;6(3):208–15.

Article  PubMed  Google Scholar 

Wiggins BS, Backes JM, Hilleman D. Statin-associated muscle symptoms—a review: individualizing the approach to optimize care. Pharmacotherapy. 2022;42(5):428–38.

Article  CAS  PubMed  Google Scholar 

Zhou Z, Albarqouni L, Breslin M, Curtis AJ, Nelson M. Statin-associated muscle symptoms (SAMS) in primary prevention for cardiovascular disease in older adults: a protocol for a systematic review and meta-analysis of randomised controlled trials. BMJ Open. 2017;7(9): e017587.

Article  PubMed  PubMed Central  Google Scholar 

Hortobagyi T, Denahan T. Variability in creatine kinase: methodological, exercise, and clinically related factors. Int J Sports Med. 1989;10(2):69–80.

Article  CAS  PubMed  Google Scholar 

Warden BA, Guyton JR, Kovacs AC, Durham JA, Jones LK, Dixon DL, et al. Assessment and management of statin-associated muscle symptoms (SAMS): a clinical perspective from the National Lipid Association. J Clin Lipidol. 2023;17(1):19–39.

Article  PubMed  Google Scholar 

Lightfoot AP, McArdle A, Jackson MJ, Cooper RG. In the idiopathic inflammatory myopathies (IIM), do reactive oxygen species (ROS) contribute to muscle weakness? Ann Rheum Dis. 2015;74(7):1340–6.

Article  CAS  PubMed  Google Scholar 

Stringer HA, Sohi GK, Maguire JA, Cote HC. Decreased skeletal muscle mitochondrial DNA in patients with statin-induced myopathy. J Neurol Sci. 2013;325(1–2):142–7.

Article  CAS  PubMed  Google Scholar 

Bouitbir J, Charles AL, Echaniz-Laguna A, Kindo M, Daussin F, Auwerx J, et al. Opposite effects of statins on mitochondria of cardiac and skeletal muscles: a “mitohormesis” mechanism involving reactive oxygen species and PGC-1. Eur Heart J. 2012;33(11):1397–407.

Article  CAS  PubMed  Google Scholar 

Singh F, Zoll J, Duthaler U, Charles AL, Panajatovic MV, Laverny G, et al. PGC-1beta modulates statin-associated myotoxicity in mice. Arch Toxicol. 2019;93(2):487–504.

Article  CAS  PubMed  Google Scholar 

Macchi C, Bonalume V, Greco MF, Mozzo M, Melfi V, Sirtori CR, et al. Impact of atorvastatin on skeletal muscle mitochondrial activity, locomotion and axonal excitability-evidence from ApoE(-/-) mice. Int J Mol Sci. 2022;23(10):5415.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zheng P, Zhang Q, Ma W, Hu R, Gu Y, Bian Z, et al. Low-dose atorvastatin protects skeletal muscle mitochondria in high-fat diet-fed mice with mitochondrial autophagy inhibition and fusion enhancement. Eur J Pharmacol. 2023;959: 176085.

Article  CAS  PubMed  Google Scholar 

Sirvent P, Bordenave S, Vermaelen M, Roels B, Vassort G, Mercier J, et al. Simvastatin induces impairment in skeletal muscle while heart is protected. Biochem Biophys Res Commun. 2005;338(3):1426–34.

Article  CAS  PubMed